Observational studyJournal of the American Heart Association2023
Intensive Statin Therapy Versus Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome: A Propensity Score Matching Analysis Based on the PL-ACS Data.
Observational study in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Guideline
- Effect of Combination Therapy with Ezetimibe and Statins versus Statin Monotherapy on Carotid Intima-Media Thickness: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Medicina (Kaunas, Lithuania) · 2023Pooled it
- Low-Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION-INCEPTION, a Randomized, Controlled, Open-Label Trial.Journal of the American Heart Association · 2026Trial
- The role of early ezetimibe combination with atorvastatin in patients with atherosclerotic cardiovascular disease.BMC cardiovascular disorders · 2026Trial
- Clinical study on the combined use of cardiovascular agents and statins in the treatment of coronary heart disease.Pakistan journal of medical sciences · 2026Article
- Potential impact on cholesterol goal achievement and predicted cardiovascular risk by the addition of ezetimibe and bempedoic acid on top of statins: a simulation from the SANTORINI study.American journal of preventive cardiology · 2026Article
- Moderate-Intensity Atorvastatin and Ezetimibe Combination Therapy Versus High-Intensity Atorvastatin in Patients with Angina Pectoris who Underwent Percutaneous Coronary Intervention.Cardiovascular drugs and therapy · 2026Article
- Effects of the 2019 guideline update on lipid-lowering therapy in patients with acute coronary syndromes.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Chinese expert consensus on the choice of initial cholesterol-lowering strategy.Frontiers in pharmacology · 2026Review
- Real-world assessment of low-density lipoprotein cholesterol goal, disease burden and financial burden among patients with atherosclerotic cardiovascular disease in Singapore-A single-centre retrospective cohort study.Frontiers in cardiovascular medicine · 2026Article
- Contemporary non-statin therapies for dyslipidemia management: achieving current lipid targets.Frontiers in medicine · 2026Review
- Dyslipidemia Treatment in Patients with Acute Coronary Syndrome: Is It Time to Move to Combination Therapy?Journal of clinical medicine · 2025Review
- Expert opinion on the integration of combination therapy into the treatment algorithm for the management of dyslipidaemia: the integration of ezetimibe and bempedoic acid may enhance goal attainment.European heart journal. Cardiovascular pharmacotherapy · 2025Review
- Article
- Lipid profile and safety of rosuvastatin monotherapy versus rosuvastatin plus ezetimibe in high risk coronary artery disease: a systematic review and meta-analysis of randomized controlled trials.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2025Review
- Combination therapy with moderate-intensity atorvastatin and ezetimibe vs. high-intensity atorvastatin monotherapy in patients treated with percutaneous coronary intervention in practice: assessing RACING generalizability.European heart journal. Cardiovascular pharmacotherapy · 2025 · on this mapObservational
- Effect of a single pill concept on clinical and pharmacoeconomic outcomes in cardiovascular diseases.European heart journal. Cardiovascular pharmacotherapy · 2025Observational
- Rosuvastatin-based combination treatment with acetylsalicylic acid or ezetimibe in the management of patients at high and very high cardiovascular risk. Expert opinion paper of the Polish Lipid Association 2025.Archives of medical science : AMS · 2025Article
- Moderate-Intensity Statin Plus Ezetimibe: Time to Rethink it as an Optimal Initial Lipid-Lowering Strategy.Drugs · 2025Review
- Ezetimibe plus statin combination versus double-dose statin in patients with dyslipidemia and atherosclerotic cardiovascular disease risk: a comprehensive systematic review and meta-analysis of 47 randomized controlled trials.Proceedings (Baylor University. Medical Center) · 2025Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background We aimed to compare statin monotherapy and upfront combination therapy of statin and ezetimibe in patients with acute coronary syndromes (ACSs). Methods and Results The study included consecutive patients with ACS included in the PL-ACS (Polish Registry of Acute Coronary Syndromes), which is a national, multicenter, ongoing, prospective observational registry that is mandatory for patients with ACS hospitalized in Poland. Data were matched using the Mahalanobis distance within propensity score matching calipers. Multivariable stepwise logistic regression analysis, including all variables, was next used in propensity score matching analysis. Finally, 38 023 consecutive patients with ACS who were discharged alive were included in the analysis. After propensity score matching, 2 groups were analyzed: statin monotherapy (atorvastatin or rosuvastatin; n=768) and upfront combination therapy of statin and ezetimibe (n=768 patients). The difference in mortality between groups was significant during the follow-up and was present at 1 (5.9% versus 3.5%;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.